Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans.
Visceral hypersensitivity is important in the pathophysiology of irritable bowel syndrome and thus a target for modulation in drug development. Neurokinin (NK) receptors, including NK(3) receptors, are expressed in the motor and sensory systems of the digestive tract. The aim of this study was to compare the effects of two different doses (25 and 100 mg) of the NK(3) receptor antagonist, talnetant (SB223412) with placebo on rectal sensory function and compliance in healthy volunteers studied at two centres. Rectal barostat tests were performed on 102 healthy volunteers, randomized to receive either oral talnetant 25 or 100 mg or placebo over 14-17 days. Studies were performed on three occasions: day 1 immediately prior to 1st dose, day 1 4 h postdose, and after 14- to17-day therapy. Compliance, and pressure thresholds for first sensation, urgency, discomfort and pain were measured using ascending method of limits, and sensory intensity ratings for gas, urgency, discomfort and pain determined during four random phasic distensions (12, 24, 36 and 48 mmHg). Talnetant had no effect on rectal compliance, sensory thresholds or intensity ratings compared with placebo. In general, the results obtained at the two centres differed minimally, with intensity scores at one centre consistently somewhat lower. At the doses tested, talnetant has no effect on rectal compliance or distension-induced rectal sensation in healthy participants.
Houghton
L A
LA
Neurogastroenterology Unit, Wythenshawe Hospital, Academic Division of Medicine and Surgery, University of Manchester, Manchester, UK.
Cremonini
F
F
Camilleri
M
M
Busciglio
I
I
Fell
C
C
Cox
V
V
Alpers
D H
DH
Dewit
O E
OE
Dukes
G E
GE
Gray
E
E
Lea
R
R
Zinsmeister
A R
AR
Whorwell
P J
PJ
D000328:Adult; D003187:Compliance / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008365:Manometry; D017288:Pain Threshold / Q000187:drug effects*; D011804:Quinolines / Q000008:administration & dosage*; D018042:Receptors, Neurokinin-3 / Q000008:administration & dosage*; D012007:Rectum / Q000187:drug effects*
D011804:Quinolines; D018042:Receptors, Neurokinin-3; C106716:SB 223412